603077 和邦生物
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)0.5010.1656.63322.82023.779
总资产报酬率 ROA (%)0.3160.1165.27618.11718.483
投入资产回报率 ROIC (%)0.3360.1275.90220.34920.486

边际利润分析
销售毛利率 (%)11.2377.80123.26142.85341.379
营业利润率 (%)3.118-0.72317.47234.36735.956
息税前利润/营业总收入 (%)3.703-0.59317.03834.53336.674
净利润/营业总收入 (%)1.290-0.82814.49129.22230.303

收益指标分析
经营活动净收益/利润总额(%)117.218-87.22697.559100.12499.254
价值变动净收益/利润总额(%)-2.4758.6334.8970.4870.753
营业外收支净额/利润总额(%)-8.4425.924-0.379-0.058-0.355

偿债能力分析
流动比率 (X)3.0662.6052.6852.6031.487
速动比率 (X)2.1141.7601.4852.0471.195
资产负债率 (%)35.94135.89617.61918.00418.329
带息债务/全部投入资本 (%)32.16731.27010.4039.68610.540
股东权益/带息债务 (%)207.167215.943851.542922.881843.249
股东权益/负债合计 (%)175.929175.007452.708440.575433.641
利息保障倍数 (X)4.475-3.384-46.256186.63543.398

营运能力分析
应收账款周转天数 (天)42.56137.64035.81117.61018.321
存货周转天数 (天)220.824204.380172.22872.18747.515